Logo image of NVNO

ENVVENO MEDICAL CORP (NVNO) Stock Fundamental Analysis

NASDAQ:NVNO - Nasdaq - US29415J1060 - Common Stock - Currency: USD

3.77  -0.05 (-1.31%)

Fundamental Rating

3

Taking everything into account, NVNO scores 3 out of 10 in our fundamental rating. NVNO was compared to 190 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NVNO as it has an excellent financial health rating, but there are worries on the profitability. NVNO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NVNO has reported negative net income.
In the past year NVNO has reported a negative cash flow from operations.
In the past 5 years NVNO always reported negative net income.
In the past 5 years NVNO always reported negative operating cash flow.
NVNO Yearly Net Income VS EBIT VS OCF VS FCFNVNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -42.15%, NVNO is doing worse than 62.23% of the companies in the same industry.
Looking at the Return On Equity, with a value of -44.84%, NVNO is in line with its industry, outperforming 51.60% of the companies in the same industry.
Industry RankSector Rank
ROA -42.15%
ROE -44.84%
ROIC N/A
ROA(3y)-45.41%
ROA(5y)-90.22%
ROE(3y)-48.33%
ROE(5y)-210.57%
ROIC(3y)N/A
ROIC(5y)N/A
NVNO Yearly ROA, ROE, ROICNVNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K -2K

1.3 Margins

NVNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVNO Yearly Profit, Operating, Gross MarginsNVNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K -20K -25K

More info and screens

8

2. Health

2.1 Basic Checks

NVNO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NVNO has been increased compared to 5 years ago.
NVNO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NVNO Yearly Shares OutstandingNVNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
NVNO Yearly Total Debt VS Total AssetsNVNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 8.67 indicates that NVNO is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.67, NVNO belongs to the best of the industry, outperforming 87.77% of the companies in the same industry.
NVNO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.67
ROIC/WACCN/A
WACCN/A
NVNO Yearly LT Debt VS Equity VS FCFNVNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

A Current Ratio of 22.01 indicates that NVNO has no problem at all paying its short term obligations.
NVNO has a Current ratio of 22.01. This is amongst the best in the industry. NVNO outperforms 99.47% of its industry peers.
NVNO has a Quick Ratio of 22.01. This indicates that NVNO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NVNO (22.01) is better than 99.47% of its industry peers.
Industry RankSector Rank
Current Ratio 22.01
Quick Ratio 22.01
NVNO Yearly Current Assets VS Current LiabilitesNVNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

NVNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.14%, which is quite impressive.
EPS 1Y (TTM)38.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NVNO will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.08% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.31%
EPS Next 2Y16.84%
EPS Next 3Y16.05%
EPS Next 5Y19.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVNO Yearly Revenue VS EstimatesNVNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
NVNO Yearly EPS VS EstimatesNVNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVNO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVNO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVNO Price Earnings VS Forward Price EarningsNVNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVNO Per share dataNVNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

NVNO's earnings are expected to grow with 16.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.84%
EPS Next 3Y16.05%

More info and screens

0

5. Dividend

5.1 Amount

NVNO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENVVENO MEDICAL CORP

NASDAQ:NVNO (2/21/2025, 8:00:01 PM)

3.77

-0.05 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)02-27 2025-02-27/amc
Inst Owners24.24%
Inst Owner Change-98.87%
Ins Owners0.93%
Ins Owner Change19.94%
Market Cap66.13M
Analysts85.71
Price Target16.83 (346.42%)
Short Float %2.6%
Short Ratio2.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.8%
Min EPS beat(2)-3.98%
Max EPS beat(2)15.58%
EPS beat(4)3
Avg EPS beat(4)14.72%
Min EPS beat(4)-3.98%
Max EPS beat(4)24.02%
EPS beat(8)5
Avg EPS beat(8)4.99%
EPS beat(12)5
Avg EPS beat(12)-23.93%
EPS beat(16)7
Avg EPS beat(16)-26.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.33%
PT rev (3m)-8.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.54%
EPS NY rev (3m)-1.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 1.4
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.95
OCFYN/A
SpS0
BVpS2.7
TBVpS2.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.15%
ROE -44.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.41%
ROA(5y)-90.22%
ROE(3y)-48.33%
ROE(5y)-210.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.09%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.01
Quick Ratio 22.01
Altman-Z 8.67
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.27%
Cap/Depr(5y)159.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y31.31%
EPS Next 2Y16.84%
EPS Next 3Y16.05%
EPS Next 5Y19.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.39%
OCF growth 3YN/A
OCF growth 5YN/A